Search This Blog

Sunday, January 31, 2010

Patient-Centered Medical Homes in Ontario (From the New England Journal of Medicine)


Walter W. Rosser, M.D., Jack M. Colwill, M.D., Jan Kasperski, R.N., M.H.Sc., and Lynn Wilson, M.D.

As the United States debates health care reform, the concept of “patient-centered medical homes” is receiving increasing attention.1 Many experts believe that medical homes with multidisciplinary teams and financial incentives for providing comprehensive care will lead to improvements in health, increase efficiency, andreduce costs of care while making practice more attractive for primary care physicians. Lessons regarding the implementation of medical homes and their ability to accomplish these goals can be gleaned from Ontario’s experience with Family Health Teams (FHTs).
Back in 1969, Canada adopted a universal health insurance program. The federal government provided partial funding, and each province developed its own health care system under national guidelines. At first, the system was well funded, and most Ontarians were satisfied. Family physicians practiced solo or in small groups and were paid on a fee-for-service basis. But by the mid-1980s, family doctors struggled to keep up with practice demands. Rising costs and either static or falling incomes pressured physicians to increase the number of patient visits, which, many observers believe, negatively affected both the quality of care and physicians’ personal lives. Interest in family medicine declined, and the proportion of Ontario medical graduates entering the field fell to 24% in 1998, though the health care system was based on the expectation that 50% of physicians would be in family practice, Canada’s only primary care specialty.
In the early 1990s, the chairs of Ontario’s five university departments of family medicine became increasingly concerned that the payment system rewarded high-volume practices rather than broad, patient-centered care.2,3 In response, a government-appointed committee identified a “basket” of services that family practicesshould provide. After physicians and politicians had been persuaded of its merits, the FHT was introduced in 2004. The FHT model is designed to expand the capacity of primary care through development of interdisciplinary teams and to improve the breadth and quality of care through incentives provided by a blended payment model. Today, about 720 physicians in 150 FHTs serve more than 1 million patients.
The model is flexible, and no two FHTs are the same. A typical practice includes at least seven family physicians and a multidisciplinary team that provides a broad range of services and 7-day-a-week access to care. Physicians sign a contract with the Ministry of Health to provide the basket of services and agree to theremuneration package. Patients wishing to receive care from an FHT must register with the Ministry and select a physician at a given practice. There is no certification process for FHTs, but electronic data, such as results of screening for colon cancer, document the services and provide information for reimbursement by the Ministry.
Primary care services focus on patient advocacy and coordination of care. Specifically included are episodic and acute care; mental health care; chronic disease care; evidence-based prevention; education for self-care; care in the hospital, at home, and in the community; support for the terminally ill; and arrangements for around-the-clock response for urgent problems. In essence, the FHT serves as the focus for all patient care, providing the majority of care and coordinating that provided by specialists and by other community resources. Not every physician delivers every service, but each group must be organized to do so. The patient’s physician sees to it that appropriate services are provided.
Physicians have responsibility for a defined panel of patients and are assisted by other health professionals, such as nurses, nurse practitioners, psychologists, pharmacists, social workers, and health educators. A typical physician panel includes about 1400 patients, smaller than a typical U.S. practice. Inclusion of a nurse practitioner adds 800 patients to the expected practice size. The Ministry provides salaries for the other health professionals and funding for an electronic record system meeting Ministry requirements.
Physician payment is based on age- and sex-based capitation that is calculated from Ontario’s fee-for-service experience. Additional fees are provided for services deemed to require added emphasis — visits for infants, for instance, or patients over 75 years of age. Physicians receive fees for procedures and for visits to hospitals, homes, and nursing homes. Graded bonuses are provided for achieving prevention goals for one’spatient panel. Family doctors receive a bonus of $100 to $300 for every new patient, depending on the complexity of that patient’s needs. The physician forfeits 1 month’s capitation fee when a patient seeks care elsewhere. About 60% of physicians’ incomes come from capitation and 40% from other fees and bonuses. Each FHT has a governing board with community representatives and is responsible for ensuring that standards are met, but standards of care are established by physicians.
Primary care reform in Ontario took more than a decade from conceptualization to implementation. Although many physicians were initially skeptical about its potential for success, as-yet-unpublished studies document high levels of patient and physician satisfaction. When the Ministry recently sought to delay expansion to 200FHTs, protests by patient groups and physicians led to cancellation of the delay.
The use of interdisciplinary teams expands the range of services provided and reduces overload for individual physicians. Since income is not based primarily on physician visits, practices can explore broader roles for team members and may use telephone, e-mail, and group visits to enhance efficiency. The total number of visits per patient has not declined, but more visits appear to be occurring with team members other than the primary physician. One study has shown that control of hypertension is better among patients in FHTs than among those in fee-for-service practices.4 The use of integrative electronic record systems appears toimprove efficiency and communication, and we believe that quality incentives have made participating physicians more proactive in providing preventive services and providing care management for chronically ill patients. A full evaluation of this model’s effects on health outcomes, quality measures, and costs will be completed in 3 to 5 years. One effect that is already obvious is an increase of approximately 40% in physicians’ incomes: the average net income for a family physician has increased from $180,000 (Canadian) in 2004 to $250,000 within FHTs, but it has not risen substantially in the fee-for-service sector.
Most Ontario teaching practices are FHTs and emphasize the values of patient-centered care in both family medicine residency programs and undergraduate medical education. The percentage of Ontario medical school graduates entering family medicine has increased from 25% in 2004 to 39% in 2009 (as compared with an increase from 24% to 29% in other Canadian provinces). Anecdotal information suggests that the first choice of Ontario’s family medicine residents is now to practice in FHTs. Family physicians who were initially skeptical are now seeking to participate.
Per capita, Canada has one third fewer active physicians than the United States, 15% more primary care physicians, and half as many specialists. Consequently, the heavy responsibilities of Canadian specialists promote shared care with family physicians, and specialists rarely see patients without referral. In the United States, only 30% of visits to specialists occur through referrals,5 and patients are likely to see multiple specialists. Canada’s physician mix has helped to contain costs, but the government recognizes that it faces shortages of both primary care and specialist physicians. Its goal is for every person to have a family physician. Ontario’s large investment in FHTs signifies its commitment to enhancing the capacity and qualityof primary care.
Could medical homes be implemented in the United States? For many in primary care, Ontario’s model represents the type of practice they always hoped to have. Already, many managed care organizations and some integrated delivery systems are headed in that direction. But multiple insurers in a region, rather than a single payer, would have to invest in the medical home for it to be viable for most primary care practices.
U.S. health care reform legislation anticipates a strong foundation of primary care — but that foundation is crumbling. Having faced similar problems, Ontario continues to convert fee-for-service practices to patient-centered medical homes, so far with positive results, including more graduates entering family medicine. Its experience can provide useful lessons for the United States as it addresses its primary care crisis.
Financial and other disclosures provided by the authors are available with the full text of this article at NEJM.org.
Source Information
From the Department of Family Medicine, Queen’s University, Kingston, ON, Canada (W.W.R.); the Department of Family and Community Medicine, University of Missouri School of Medicine, Columbia (J.M.C.); the Ontario College of Family Physicians, Toronto (J.K.); and the Department of Family and Community Medicine, University of Toronto, Toronto (L.W.).
This article (10.1056/NEJMp0911519) was published on January 6, 2010, at NEJM.org.
References
  1. The patient centered medical home: history, seven core features, evidence and transformational change. Washington, DC: Robert Graham Center, November 2007. (Accessed January 5, 2010, at http://www.graham-center.org/online/etc/medialib/graham/documents/publications/mongraphs-books/2007/rgcmo-medical-home.Par.0001.File.tmp/rgcmo-medical-home.pdf.)
  2. Forster J, Rosser W, Hennen B, McAuley R, Wilson R, Grogan M. New approach to primary medical care: nine-point plan for a family practice service. Can Fam Physician 1994;40:1523-1530. [Web of Science][Medline]
  3. Rosser WW, Kasperski J. Organizing primary care for an integrated system. Healthc Pap 1999;1:5-21. [Medline]
  4. Tu K, Cauch-Dudek K, Chen Z. Comparison of primary care physician payment models in the management of hypertension. Can Fam Physician 2009;55:719-727. [Free Full Text]
  5. Valderas JM, Starfield B, Forrest CB, Sibbald B, Roland M. Ambulatory care provided by office-based specialists in the United States. Ann Fam Med 2009;7:104-110. [Free Full Text]

Friday, January 29, 2010

MU Researcher Developing New Preventive Agent for Stopping Spread of HIV

Tests show EFdA is much more effective than other microbicides

Nearly 30 years after the discovery of the virus that causes AIDS, contracting the disease is no longer a quick death sentence. While high-tech therapies help patients live longer, healthier lives, one University of Missouri researcher is fighting HIV on another level — with a microbicide that stops the virus in its tracks.

Stefan Sarafianos, PhD, assistant professor of microbiology and immunology in the MU School of Medicine, and his collaborators Michael Parniak, PhD, at the University of Pittsburgh and Hiroaki Mitsuya, MD, PHD, at the National Institutes of Health have shown that the molecule EFdA can be used as a highly effective microbicide to prevent HIV transmission. They are in the process of patenting the chemical compound, which is up to 60,000 times more powerful than any other drug currently used for the treatment of HIV infection.

EFdA is a nucleoside reverse transcriptase inhibitor, meaning it targets the main HIV enzyme responsible for viral replication. In laboratory tests, human cells treated with EFdA can still become infected with HIV, but the compound stops the virus from replicating and spreading. Then, the immune system rids cells of the invader.

“The immune system has the capability to kill a little of the virus in the background, so it becomes manageable,” Sarafianos said. “Infection is the result of an overwhelming attack of the virus, but if you manage to keep the viral load low, the body has mechanisms to defend itself and clean up the virus on its own.”

With HIV vaccine efforts at an impasse, increased emphasis is placed on the discovery of alternate strategies to prevent HIV infection. Internationally, researchers are focused on developing microbicides that contain the same or related antiretroviral drugs used as treatments for people infected with HIV. Scientists hope the drugs can double as preventive agents in the form of vaginal gels and creams, empowering women to protect themselves when their partners refuse to use condoms.

One of the most popular drugs, tenofovir, is being tested as a microbicide in gel form. When EFdA is tested head-to-head with tenofovir in lab trials, there’s no competition, Sarafianos said.

“EFdA provides a much longer-term barrier to HIV infection, up to days whereas other microbicides last hours,” Sarafianos said. “EFdA also has a low toxicity against normal cells, and it is active against a broad spectrum of HIV subtypes.”

Sarafianos co-investigator Michael Parniak, a professor of microbiology and molecular genetics, has spent more than 15 years studying and developing antiviral drugs for HIV/AIDS. His work in this area has resulted in eight patents issued or pending. Along with EFdA, he is developing the antiviral drug UC781, which is currently in clinical trials as a microbicide to prevent HIV transmission.

Parniak calls EFdA the most potent HIV inhibitor discovered so far.

“To me, this is the molecule that should and will move forward as a microbicide,” Parniak said. “A combination of EFdA and UC781 would be a powerhouse, a one-two punch pretty much guaranteeing significant blockage of HIV transmission.”

Just as an EFdA and UC781 combination could someday knockout HIV, Sarafianos and Parniak posses a dynamic and complementary working relationship. Parniak, who specializes in virology, is the principal investigator for the microbicidal use of EFdA, while Sarafianos is the biochemical expert and principal investigator for work to understand EFdA’s mechanism of action — he understands precisely how EFdA works against the virus.
Sarafianos, Parniak and Hiroaki Mitsuya, head of the experimental retrovirology section at the NIH and inventor of several approved HIV drugs, recently submitted a patent disclosure. The scientists now have one year to apply for a patent to use EFdA, originally synthesized by the Japanese company Yamasa, to minimize the sexual transmission of HIV. Once patented, the microbicide could be integrated into a product already commonly used for protection during sexual intercourse, such as a spermicide or other form of birth control.

“If we can reduce the transmission of HIV, we can finally get a handle on overall infection spread,” Parniak said. “If we could reduce HIV transmission by only 30 percent or 40 percent, that would make a huge difference.”

According to estimates by the World Health Organization and UNAIDS, 33 million people were living with HIV at the end of 2007. That same year, some 2.7 million people became newly infected, and 2 million died of AIDS, including 270 000 children.

In the distant future, EFdA could also evolve into a treatment for patients already infected with HIV. In a study conducted by Parniak at the University of Pittsburgh, EFdA effectively treated rhesus monkeys infected with simian immunodeficiency virus (SIV) who showed end-stage simian AIDS symptoms. Monkeys with end-stage SAIDS typically die within a few weeks; the EFdA-treated animals lived for more than six months, a positive predictor that EFdA could have a similar effect in humans.

Parniak attributes much of EFdA’s potential to the novel mechanism of action discovered by Sarafianos’ lab at MU.

“He’s so excited about research, that he recharges me every time,” Parniak said of their weekly conversations to share data. “He’s one of our brightest young investigators and a real gem for Mizzou.”

The investigators’ EFdA research is funded by seven grants. Funding sources include multiple NIH grants, a grant from the American Foundation for AIDS Research and indirect federal funding of Sarafianos’ lab in MU’s Christopher S. Bond Life Sciences Center.

Thursday, January 28, 2010

More on the Stroke Belt study (From the Harvard Health Letter)


Maria Glymour and her colleagues at the Harvard School of Public Health conducted their study of the Stroke Belt by using data from the 1980, 1990, and 2000 censuses and mortality data from the National Center for Health Statistics for those same years. One of the strengths of their study was the use of “hard” mortality data, which is based on official death certificates.
They defined the Stroke Belt as being the states of North Carolina, South Carolina, Georgia, Alabama, Mississippi, Tennessee, and Arkansas. These are the seven states included in the federal government’sStroke Belt elimination project.
Using the census and mortality data, the researchers created four “exposure” categories, with the exposure being either birth in the Stroke Belt or residence in a Stroke Belt state as an adult. The exposure groups stack up like this:

  • Born in the Stroke Belt, adulthood in the Stroke Belt (double exposure)

  • Born in the Stroke Belt, adulthood out of the Stroke Belt (out-migrants)

  • Not born in the Stroke Belt, adulthood in the Stroke Belt (in-migrants)

  • Not born in the Stroke Belt, adulthood out of the Stroke Belt (no exposure)

Crude rates

Once the exposure groups were set, the researchers then calculated the number of stroke deaths per 100,000 people — the crude stroke mortality rate — for each of them. Here are the results:
1980
1990
2000
Stroke Belt birth, Stroke Belt adulthood (doubly exposed)
122
83
74
Stroke Belt birth, non-Stroke Belt adulthood (out-migrants)
115
89
88
Non-Stroke Belt birth, Stroke Belt adulthood (in-migrants)
63
43
39
Non-Stroke Belt birth, non-Stroke Belt adulthood (nonexposed)
78
52
47
Here is the same information just for whites:
1980
1990
2000
Stroke Belt birth, Stroke Belt adulthood (doubly exposed)
97
68
66
Stroke Belt birth, non-Stroke Belt adulthood (out-migrants)
86
65
66
Non-Stroke Belt birth, Stroke Belt adulthood (in-migrants)
60
41
40
Non-Stroke Belt birth, non-Stroke Belt adulthood (nonexposed)
75
51
46
And for blacks:
1980
1990
2000
Stroke Belt birth, Stroke Belt adulthood (doubly exposed)
211
128
96
Stroke Belt birth, non-Stroke Belt adulthood (out-migrants)
146
115
116
Non-Stroke Belt birth, Stroke Belt adulthood (in-migrants)
112
66
37
Non-Stroke Belt birth, non-Stroke Belt adulthood (nonexposed)
112
68
58
Note that in almost every category, the stroke mortality rate is higher for blacks. The lone exceptions are the so-called in-migrants — people who moved to the Stroke Belt after living elsewhere.
Glymour and her colleagues pointed out that excess stroke mortality from Stroke Belt exposure, either at birth or as an adult, declined from 1980 to 2000 in every category. The biggest decline was among blacks who were “doubly exposed” (from a rate of 211 stroke deaths per 100,000 people in 1980 to a rate of 96 stroke deaths per 100,000 in 2000).

More refined numbers

But these are crude mortality rates that don’t take into account sex and age. The researchers made those adjustments. They also expressed the stroke risk as an odds ratio relative to the nonexposed group. In simplified terms, that means calculating how much greater the stroke risk was for people who had spent time in the Stroke Belt (birth, adulthood, or both) compared with the stroke risk for those who were neither born nor lived there as adults — the nonexposed in the charts above.
So, for example, in the chart below, 45% means a 45% greater chance of having a stroke than the nonexposed group. Here are those results for whites:
1980
1990
2000
Stroke Belt birth, Stroke Belt adulthood (doubly exposed)
45%
29%
34%
Stroke Belt birth, non-Stroke Belt adulthood out (out-migrants)
31%
20%
20%
Non-Stroke Belt birth, Stroke Belt adulthood (in-migrants)
8%
7%
11%
For blacks:
1980
1990
2000
Stroke Belt birth, Stroke Belt adulthood (doubly exposed)
55%
47%
34%
Stroke Belt birth, non-Stroke Belt adulthood out (out-migrants)
20%
11%
9%
Non-Stroke Belt birth, Stroke Belt adulthood (in-migrants)
13%
49%
1%
The highest group for whites and blacks are the doubly exposed, although by 2000, there is no racial difference: the stroke death rate is 34% higher for both whites and blacks. It’s also interesting that the stroke risk for out-migrant blacks is lower than it is for out-migrant whites in all three years.
Glymour and her colleagues acknowledge that their study cannot answer perhaps the most interesting question: Why is there a Stroke Belt in the first place? Genetic explanations don’t seem to work, because the Stroke Belt effect is true for both blacks and whites, although it’s usually less pronounced in whites. Behaviors or perhaps environmental toxins of some sort are more likely explanations, but nobody knows for sure.
This study does raise new questions about timing and whether there might be something about being born and spending your early childhood (place of birth and place of early childhood are not the same but census information shows that they are closely related) in the American Southeast that leads to a greater chance of having a fatal stroke later in life.